Use of selinexor with ibrutinib to overcome ib... - CLL Support

CLL Support

23,339 members40,047 posts

Use of selinexor with ibrutinib to overcome ibrutinib resistance

1 Reply

New study involving the use of selinexor to overcome ibrutinib resistance is seen as a “breakthrough” by some people who are undoubtedly smarter than me. Interesting stuff, the plain English explanation is contained at “Breakthrough Increases Efficacy of B-Cell Lymphoid Malignancy Treatment”.

ajmc.com/newsroom/breakthro...

The far more complicated study itself is at “Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies”.

researchgate.net/publicatio...

I would like to think of this as a Christmas present for those of us who have encountered Ibrutinib resistance.

Merry Christmas,

Owen

Read more about...
1 Reply
lankisterguy profile image
lankisterguyVolunteer

Hi SlowCLL,

Thanks for posting those two links. Interesting reading for those of us that have developed resistance.

I'm actually resistant to Zydelig/Idelalisib and intolerant of side effects from Imbruvica/Ibrutinib, so I look for information like those papers.

Len

Not what you're looking for?

You may also like...

Hypertension and cardiovascular events following ibrutinib initiation

I thought it worth reiterating the high level of hypertension (HT) reported in patients treated...
Jm954 profile image
Administrator

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters

Several of us have reported our CLL symptoms have come roaring back after discontinuing...
AussieNeil profile image
Partner

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator